Drug Profile
Research programme: Mesd therapeutics - Horizon Therapeutics plc
Alternative Names: WntTideLatest Information Update: 06 Nov 2023
Price :
$50
*
At a glance
- Originator Washington University
- Developer Raptor Pharmaceutical Corp; Washington University
- Class Proteins
- Mechanism of Action Wnt protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Breast cancer
Highest Development Phases
- Discontinued Osteoporosis; Triple negative breast cancer
Most Recent Events
- 02 May 2019 Horizon Pharma is now called Horizon Therapeutics plc
- 12 Aug 2014 Discontinued - Preclinical for Osteoporosis in USA (unspecified route)
- 12 Aug 2014 Discontinued - Preclinical for Triple negative Breast cancer in USA (unspecified route)